Bristol Myers Squibb, US1101221083

Bristol Myers Squibb stock at EUR 57.52, up 1.54%

Published on 11/16/2026 at 08:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb develops and commercializes medicines across oncology, hematology and other therapeutic areas. On Xetra, the stock closed at EUR 56.65 on Friday, November 13, 2026.

Business and market focus

  • Bristol Myers Squibb operates as a global biopharmaceutical company spanning research, development, production and commercialization.
  • Its portfolio covers oncology, hematology, cardiovascular health, immunology, neuroscience and infectious diseases.
Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock traded at 57.52 euros on Lang & Schwarz at 08:51 CET on Monday, November 16, 2026, 1.54 percent above the Xetra close of Friday, November 13, at EUR 56.65.

Bristol Myers Squibb operates as a global biopharmaceutical company that researches, develops, produces and commercializes medicines across several therapeutic areas.

US equities will be tracked through the S&P 500.

More news and analyses on Bristol Myers Squibb stock

Disclaimer...
en | US1101221083 | BRISTOL MYERS SQUIBB | boerse | 70519902 | bgmi